Last updated: May 26, 2026
ADEMPAS (riociguat) suppliers: API, finished-dose manufacturers, and distribution sources
ADEMPAS is marketed as Bayer’s riociguat product for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The supplier landscape splits into (1) riociguat active pharmaceutical ingredient (API) manufacturers, (2) finished-dose/tablet manufacturing and packaging sites, and (3) distribution channels that supply pharmacies and wholesalers. A defensible supplier map requires linking Bayer’s labeled product to current FDA drug listing/Orange Book entries and market authorizations; that information is not provided here, so a complete and accurate supplier identification cannot be produced.
Which companies supply ADEMPAS riociguat API and where is it made?
A complete API supplier list requires the API manufacturer(s) tied to ADEMPAS’s FDA regulatory filings (FDA drug application components and Orange Book “Applicant/Manufacturer” and listing data). Without those listing identifiers and dates, no accurate API supplier attribution can be made.
What’s the API supply chain structure for riociguat tablets?
Typical inputs for a commercially marketed oral small molecule include:
- Riociguat API synthesis and purification at one or more GMP sites
- Blending and tableting at a finished-dose GMP site
- Secondary packaging (bottles/blisters) and distribution readiness
But supplier-specific names and plant locations must be sourced from FDA listings or equivalent regulatory documentation.
Who manufactures ADEMPAS finished tablets (10 mg, 1 mg, 0.5 mg) and packs them?
Finished-dose supplier identification also depends on the FDA listing fields for:
- Applicant/Manufacturer for the marketed strength(s)
- Dosage form and strength-specific manufacturing and packaging sites
- Repackagers/labelers, if any
Without access to those specific listing records for ADEMPAS, naming tablet manufacturers or packaging suppliers risks being incorrect.
How do strength-specific manufacturers differ for ADEMPAS?
Strength-by-strength manufacturing differences are common for controlled-dose titration products. Identifying them requires strength-level manufacturing site data (site codes and addresses) from current FDA listings and label agreements.
What is the Orange Book status of ADEMPAS and does it list manufacturing sites?
The FDA Orange Book typically lists:
- Patents and exclusivities
- Applicant/Manufacturer for the listed drug
- Drug application references (NDA)
But the Orange Book data needed to determine ADEMPAS listing details (NDA number and current manufacturer fields) is not included here. Therefore, a precise Orange Book status and supplier list cannot be stated.
How many supplier sites feed ADEMPAS distribution in the US?
Counting distinct supplier sites (API and finished-dose) requires:
- Current FDA drug listing entries
- Current US distribution label/packaging labeler and manufacturing site data
- Any subsequent site transfers and supplements
No listing dataset is provided here, so the number of supplier sites cannot be stated.
Which distributors supply ADEMPAS to pharmacies and wholesalers?
Distribution suppliers are generally identified via:
- Wholesaler distribution records (private commercial datasets)
- Labeler/manufacturer distribution annotations tied to FDA labelers
- Contract logistics networks for specialty pharmaceuticals
No distribution channel dataset is provided, so distributor names cannot be accurately mapped.
What generic or biosimilar entry risks affect ADEMPAS suppliers?
ADEMPAS is a small-molecule drug (not a biologic), so the relevant competitive pressure is from generics and potential authorized generics, not biosimilars. Generic entry risk also depends on:
- Patent and exclusivity expiration dates
- Paragraph IV litigation history and settlements
- FDA approval status of ANDAs
Those legal and regulatory milestones are not included here, so supplier-impact conclusions cannot be made.
What patent landscape issues drive supplier qualification for ADEMPAS?
Supplier qualification for a reference product often intersects with:
- Brand exclusivity and listing strategy
- Patent-triggered manufacturing and labeling constraints
- Commercial supply continuity tied to regulatory listings
A patent landscape cannot be asserted here without the Orange Book record and litigation docket details.
ADEMPAS vs. other riociguat products: do suppliers overlap?
No alternate riociguat branded products are identified here, and supplier overlap requires:
- Confirmed labeled products and their respective NDA/marketing authorizations
- Their supplier/manufacturing site mappings
Without those cross-references, overlap cannot be determined.
Key Takeaways
- ADEMPAS supplier identification requires current FDA listing-level data linking ADEMPAS (riociguat) to named API manufacturers, finished-dose manufacturers, packaging sites, and labelers/distributors.
- No FDA listing, Orange Book entry, NDA number, or regulatory dataset is provided in the prompt, so a complete and accurate supplier list cannot be produced.
FAQs
- What is the NDA number for ADEMPAS and does it map to multiple manufacturing sites?
- Which riociguat API manufacturers are listed for ADEMPAS in FDA records?
- Do ADEMPAS tablet packaging and labeling operations differ by strength?
- What does the Orange Book list as the applicant/manufacturer for ADEMPAS?
- How do patent and exclusivity events affect third-party manufacturing of ADEMPAS-equivalent formulations?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drugs@FDA: FDA Approved Drug Products. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
